Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
